Summer 2026 CCSN Survey for Patient/Caregiver Input on Pre-Chemotherapy Myeloprotectant for Extensive Stage Small Cell Lung Cancer - trilaciclib |
The pan-Canadian Oncology Drug Review invites patient groups to prepare and send in submissions so that individuals with lived experience, like you, can be heard. Please join us and have your voice included in this important submission process. All information provided will remain anonymous when used in the submission.
The purpose of this survey is to provide the Canadian Cancer Survivor Network and its partners with insights and perspectives about living with lung cancer from survivors, patients and caregivers in order to complete a patient evidence submission for new treatments that are under review in Canada.
The proposed indication is currently undergoing review at Health Canada, and is expected to be considered for a reimbursement review at Canada's Drug Agency and L’Institut national d’excellence en santé et en services sociaux (INESSS):
Trilaciclib (brand name = Cosela) for the prevention of chemotherapy-induced myelosuppression when administered as a component of platinum/etoposide- or topotecan-containing regimens for extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is also sometimes refered to as Metastatic Small Cell Lung Cancer.
If you are outside of this specification and feel you may also benefit from this treatment, we would like to hear from you as well. Your input could help inform what is desired from patients and caregivers in new and upcoming medications and treatments.
This survey should take approximately 30-35 minutes to complete and will remain open until end of day Sunday November 8, 2026.
Only questions marked with an asterisk are mandatory.
Please be sure to press the "Done" button a the end of the survey to ensure your answers are recorded.
Thank you for your participation!
The purpose of this survey is to provide the Canadian Cancer Survivor Network and its partners with insights and perspectives about living with lung cancer from survivors, patients and caregivers in order to complete a patient evidence submission for new treatments that are under review in Canada.
The proposed indication is currently undergoing review at Health Canada, and is expected to be considered for a reimbursement review at Canada's Drug Agency and L’Institut national d’excellence en santé et en services sociaux (INESSS):
Trilaciclib (brand name = Cosela) for the prevention of chemotherapy-induced myelosuppression when administered as a component of platinum/etoposide- or topotecan-containing regimens for extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is also sometimes refered to as Metastatic Small Cell Lung Cancer.
If you are outside of this specification and feel you may also benefit from this treatment, we would like to hear from you as well. Your input could help inform what is desired from patients and caregivers in new and upcoming medications and treatments.
This survey should take approximately 30-35 minutes to complete and will remain open until end of day Sunday November 8, 2026.
Only questions marked with an asterisk are mandatory.
Please be sure to press the "Done" button a the end of the survey to ensure your answers are recorded.
Thank you for your participation!